Ablative Radioembolization of Renal Cell Carcinoma Trial

Renal cell carcinoma (RCC), the most common type of kidney cancer, is typically treated with surgery; however, there is no established therapy for patients who are not surgical candidates and who have tumours greater than 4.0 cm in size. Selective internal radiation therapy (SIRT) or radioembolization using radioactive spheres containing 90-Yttrium (Y-90) is successful at treating large tumours with high doses of radiation within the liver and might be similarly effective for treating larger RCC tumours in patients, particularly those who are not surgical candidates. This prospective study wi

Trial Details

NCT ID

NCT06642220

Phase

PHASE2

Sponsor

Derek W. Cool

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Y-90 Selective Internal Radiation Therapy (SIRT)

Locations (sample)

London, Ontario, Canada|42.98339,-81.23304

Key Eligibility Criteria

Patients willing to participate and provide written consent
Patients 18 years of age and older
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2
Biopsy confirmed RCC \> 4.0 cm and no renal vein or IVC involvement (T1b or T2 disease)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →